Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
10,816,370
-
Shares change
-
+440,181
-
Total reported value, excl. options
-
$103,998,595
-
Value change
-
+$4,177,290
-
Number of buys
-
35
-
Number of sells
-
-17
-
Price
-
$9.61
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q4 2019
67 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2019.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10,816,370 shares
of 55,705,828 outstanding shares and own 19% of the company stock.
Largest 10 shareholders include Atlas Venture Associates IX, LLC (1,376,968 shares), Aquilo Capital Management, LLC (1,154,356 shares), Alphabet Inc. (1,112,473 shares), Novo Holdings A/S (931,099 shares), BVF INC/IL (845,405 shares), BlackRock Inc. (755,265 shares), Rock Springs Capital Management LP (525,000 shares), Artal Group S.A. (500,000 shares), VANGUARD GROUP INC (496,401 shares), and AWM Investment Company, Inc. (474,344 shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.